3B Pharmaceuticals GmbH
🇩🇪Germany
Clinical Trials
1
Active:0
Completed:0
Trial Phases
1 Phases
Phase 1:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (1 trials with phase data)• Click on a phase to view related trials
Phase 1
1 (100.0%)A Study of [225Ac]-FPI-2059 in Adult Participants With Solid Tumours
Phase 1
Terminated
- Conditions
- Gastric CancerPancreatic Ductal Adenocarcinoma (PDAC)Colorectal CancerSquamous Cell Carcinoma of Head and NeckNeuroendocrine Differentiated (NED) Prostate CancerEwing SarcomaNTSR1 Expressing Solid Tumours
- Interventions
- First Posted Date
- 2022-11-04
- Last Posted Date
- 2025-08-19
- Lead Sponsor
- 3B Pharmaceuticals GmbH
- Target Recruit Count
- 19
- Registration Number
- NCT05605522
- Locations
- 🇺🇸
University of Alabama at Birmingham Hospital, Birmingham, Alabama, United States
🇺🇸City of Hope Medical Center, Duarte, California, United States
🇺🇸Hoag Family Cancer Institute, Newport Beach, California, United States
News
ITM and Debiopharm Initiate New Study Arm for CAIX-Targeted Theranostic in Clear Cell Renal Cell Carcinoma
ITM and Debiopharm announced the first patient imaging in Part D of their Phase 1/2 trial evaluating ITM-94 as a diagnostic agent for clear cell renal cell carcinoma.